David C. Dalgarno, D.Phil., is a distinguished oncology drug discovery leader, technology strategist, and seasoned executive whose career spans more than four decades across biotechnology, pharmaceuticals and research innovation. Known for his rare combination of deep scientific expertise and visionary operational leadership, David has helped refine and elevate modern approaches to small molecule drug discovery by integrating structural biology, biophysics, computational chemistry with accessible data into cohesive, high-performing research ecosystems. This effort has directly contributed to multiple FDA-approved therapies in precision oncology through a career grounded in scientific excellence, intellectual curiosity, and a profound commitment to mentorship.

David’s journey began at the University of Oxford, where he earned both his B.A. and D.Phil. degrees in Chemistry, with an emphasis on physical and inorganic chemistry. His academic foundation—rooted in rigorous Chemistry teaching and in engagement with novel multi-disciplinary teams driving understanding of complex biochemical systems—laid the groundwork for his postdoctoral research at Yale University in Molecular Biophysics and Biochemistry. This early phase of his career revealed a natural inclination toward applying core scientific principles to practical, high-impact discovery challenges, ultimately shaping his trajectory toward industrial drug development.

David launched his career in pharmaceuticals at Schering-Plough Corporation, where he distinguished himself as a gifted researcher with a strong aptitude for navigating structural, analytical, and mechanistic complexities. His contributions earned him a Schering-Plough President’s Award and set the stage for his transition into oncology-focused R&D. Yet it was at ARIAD Pharmaceuticals—where David spent 25 influential years—that his leadership matured into a respected scientific voice.

During his tenure at ARIAD, David led cross-disciplinary teams encompassing structural biology, biochemistry, biophysics, computational chemistry, and cheminformatics, ultimately shaping the company’s strategy for structure-based drug design. Using these tools, his team contributed to the discovery and development of the kinase targeted oncology therapies: ponatinib, brigatinib, and mobocertinib.  Each therapy can overcome on-target drug resistance, focusing David’s goal to integrate deep mechanistic understanding with practical drug design applications.

As he advanced into executive leadership—including roles as Vice President of Research Technologies and Vice President of Development Sciences—David forged pathways for integrating data, digital systems, and operational processes across R&D functions. To provide scientists with the tools necessary to innovate faster and more effectively, he led initiatives in data governance, sample storage and tracking, automated data reduction, upload and visualization, and by enabling efficient equipment purchases. His leadership, grounded in collaboration and robust scientific strategy, strengthened ARIAD’s technological and analytic infrastructure, enabling smoother laboratory operations, clearer data access, and more efficient progression from target identification through IND-enabling studies. 

David’s entrepreneurial spirit emerged with the co-founding of Theseus Pharmaceuticals, where he served as Chief Technology Officer. In this role, he helped shape the company’s scientific, digital, and operational strategy from inception, enabling foundational workflows, CRO partnerships, and data management that propelled early discovery programs forward. His leadership helped position Theseus Pharmaceuticals as a forward-thinking oncology company equipped to address drug resistance challenges through smart design and experience-driven computational approaches.

In 2024, David joined Kojin Therapeutics as Senior Vice President of Digital & Data Science and Technology, where he continued to champion digital transformation in drug discovery, expanding computational capabilities and accelerating instrument acquisition. His tenure reinforced his reputation as an executive who not only understands the scientific landscape but also anticipates the technological advances that will define the future of therapeutic discovery.

Beyond his corporate success, David is widely regarded as an advocate for cross-disciplinary knowledge sharing and scientific mentorship. He has shaped the careers of emerging scientists by modeling intellectual curiosity, strategic rigor, and ethical leadership. As Chair of the U.S. Development Committee for Robert Gordon’s College in Scotland, he supports the school’s educational development initiatives and can inspire the next generation of scientific leaders. This commitment to service and mentorship reflects David’s belief that scientific progress is driven not only by breakthrough discoveries but by building cultures where people are empowered to learn, question boldly, and innovate responsibly.

David’s scholarly impact is extensive, with more than 60 peer-reviewed publications and co-inventorship on more than 15 patents related to kinase inhibitors and targeted oncology therapies. His influence spans both academic and industrial settings, where he is respected for advancing the understanding of drug resistance mechanisms and designing molecular strategies to overcome them. His contributions to science, technology integration, and workflow optimization remain models for new companies entering early discovery and lead optimization towards pre-clinical development.

Today, David remains driven by the same intellectual energy and mission-oriented mindset that defined the earliest stages of his career. He brings a unique blend of scientific precision, strategic foresight, and people-centered leadership to every organization he supports. Whether advising executive teams, optimizing research infrastructure, or engaging in scientific thought leadership, he approaches every opportunity with unwavering integrity, deep curiosity, and a passion for solving complex scientific challenges that make a tangible difference in patients’ lives.

Character:
David is guided by a strong sense of integrity, ensuring that scientific truth and ethical principles remain central to all decision-making. He approaches leadership with humility and empathy, fostering environments where colleagues feel valued and inspired to contribute their best work. His dedication to mentorship reflects his belief that developing people is as important as developing therapies.

Knowledge:
His expertise spans structural biology, drug design, computational chemistry, biophysics, and digital transformation, enabling him to navigate complex scientific challenges with clarity and precision. He continuously expands his knowledge to stay at the forefront of emerging technologies that shape modern drug discovery. His extensive publication and patent record demonstrates a lifelong commitment to rigorous inquiry and scientific contribution.

Strategic:
David excels in translating scientific complexity into pragmatic strategies that advance programs efficiently and effectively. He anticipates industry shifts and positions teams to thrive through innovative systems, data governance, and collaborative workflows. His strategic insight helps guide organizations through key R&D decisions, operational transformations, and scientific scaling efforts.

Communication:
A clear, thoughtful communicator who excels in bridging scientific and technical domains to ensure shared understanding across diverse teams. He articulates complex concepts with precision while fostering open dialogue that strengthens collaboration. His communication style empowers others by making science accessible, actionable, and engaging.